The Obesity Action Coalition (OAC) is pleased to share that Rhythm Pharmaceuticals has renewed its support of OAC at the Bronze level as a member of our Chairman’s Council. Thank you, Rhythm, for continuing to support and champion the OAC’s mission!
About Rhythm Pharmaceuticals, Inc.
Rhythm is a commercial-stage biopharmaceutical company committed to transforming the treatment paradigm for people living with rare genetic diseases of obesity. The company’s precision medicine, IMCIVREE™ (setmelanotide), has been approved by the FDA for chronic weight management in adult and pediatric patients 6 years of age and older with obesity due to POMC, PCSK1 or LEPR deficiency confirmed by genetic testing. IMCIVREE™ is the first-ever FDA-approved therapy for these rare genetic diseases of obesity. Rhythm is advancing a broad clinical development program for setmelanotide in other rare genetic diseases of obesity. To learn more about Rhythm, click here.
About OAC’s Chairman’s Council
The OAC is grateful that Rhythm has renewed its Bronze level support of our organization through the Chairman’s Council, as we strive to partner with industry leaders who share in our mission of supporting individuals affected by obesity through education and advocacy.
The OAC welcomes ANY individual, organization or company who wishes to join our highest level of OAC Membership and receive maximum benefits. Our Chairman’s Council is an excellent way to give back to our cause and play an integral role in making the world a better place for people with obesity. To learn more about the OAC’s Chairman’s Council, click here.